| Clinically isolated syndrome

Aubagio vs Rebif

Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.
Deep comparison between: Aubagio vs Rebif with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsRebif has a higher rate of injection site reactions vs Aubagio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rebif but not Aubagio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Aubagio
Rebif
At A Glance
Oral
Daily
Pyrimidine synthesis inhibitor
SC injection
Three times per week
Interferon beta-1a
Indications
  • Multiple Sclerosis, Secondary Progressive
  • Clinically isolated syndrome
  • Clinically isolated syndrome
  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple Sclerosis, Secondary Progressive
Dosing
Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 7 mg or 14 mg orally once daily; may be taken with or without food.
Clinically isolated syndrome, Multiple Sclerosis Relapsing-Remitting, Multiple Sclerosis Secondary Progressive 22 mcg or 44 mcg SC three times per week; titrate starting at 20% of prescribed dose over a 4-week period to the targeted dose; administer at the same time on the same three days at least 48 hours apart each week.
Contraindications
  • Severe hepatic impairment
  • Pregnancy or females of reproductive potential not using effective contraception
  • History of hypersensitivity reaction to teriflunomide, leflunomide, or any inactive ingredient (including anaphylaxis, angioedema, or serious skin reactions)
  • Coadministration with leflunomide
  • History of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation
Adverse Reactions
Most common (>=2% above placebo) Headache, increased alanine aminotransferase, diarrhea, alopecia, nausea, paresthesia, arthralgia, neutropenia, hypertension
Serious Hepatotoxicity, bone marrow effects/immunosuppression/infections, hypersensitivity reactions, serious skin reactions, DRESS, cutaneous or mucocutaneous ulcers and impaired wound healing, peripheral neuropathy, increased blood pressure, respiratory effects, pancreatitis (pediatric patients)
Postmarketing Thrombocytopenia, pancreatitis, colitis, drug-induced liver injury, anaphylaxis, angioedema, interstitial lung disease, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS, psoriasis (including pustular and nail), nail disorders, cutaneous or mucocutaneous ulcers, impaired wound healing
Most common Injection site reaction, influenza-like symptoms, headache, fatigue, fever, leukopenia, elevated liver enzymes (SGPT, SGOT), myalgia, back pain, abdominal pain, depression
Serious Depression and suicide, hepatic injury, anaphylaxis and other allergic reactions, injection site necrosis, decreased peripheral blood counts, thrombotic microangiopathy, pulmonary arterial hypertension, seizures
Postmarketing Drug-induced lupus erythematosus, autoimmune hepatitis, retinal vascular disorders, pulmonary arterial hypertension, erythema multiforme, Stevens-Johnson syndrome, hemolytic anemia
Pharmacology
Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme required for de novo pyrimidine synthesis, which may reduce the number of activated lymphocytes in the CNS.
Interferon beta-1a; the exact mechanism(s) by which REBIF exerts its therapeutic effects in multiple sclerosis is unknown, but it is a recombinant form of human interferon beta produced in Chinese Hamster Ovary cells with an amino acid sequence identical to natural fibroblast-derived human interferon beta.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aubagio
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (4/12)
View full coverage details ›
Rebif
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Aubagio
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
View full coverage details ›
Rebif
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
View full coverage details ›
Humana
Aubagio
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
View full coverage details ›
Rebif
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
AubagioView full Aubagio profile
RebifView full Rebif profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.